抗苗勒管激素自动化检测方法不等效——作为个体化促卵泡激素δ给药伴随诊断的临床意义
本研究系统检索文献并汇总6项研究848名女性的配对抗苗勒管激素(AMH)数据,比较Elecsys®与Access两种自动化免疫检测法。Passing-Bablok回归显示Access= -0.05 + 1.10 × Elecsys,Access法平均高10%(斜率1.10,95%CI 1.09至1.12),若以Access替代Elecsys作为促卵泡激素δ的伴随诊断,253名(29.3%)女性会被错误分类到不同剂量。
要点
- Access法AMH值系统性地高于Elecsys®法,平均高10%(斜率1.10,95%CI 1.09至1.12)。
- 若用Access法替代Elecsys作为促卵泡激素δ伴随诊断,253名(29.3%)女性会被错误分类到不同剂量。
- 根据AMH类别不同,49%至90%的女性会基于Access法AMH接受较低剂量的促卵泡激素δ。
核心结论
- Access检测法给出的AMH值系统性地高于Elecsys®检测法,导致超过29%的女性被错误分类到不同的促卵泡激素δ剂量。
- 需要建立自动化AMH检测的国际校准标准,以促进AMH作为伴随诊断的有效使用。
研究设计与样本
- 系统检索现有文献中在同一女性队列中同时使用两种自动化检测法测量AMH的研究。
- 从每位作者获取个体配对患者数据并与未发表数据合并,共纳入5项已发表的前瞻性研究和1项额外的未发表研究,获得848名女性的配对AMH样本数据。
主要发现
- Passing-Bablok回归显示线性关系:Access = -0.05 + 1.10 × Elecsys。
- Access检测法平均比Elecsys检测法高10%(斜率=1.10,95%CI:1.09至1.12),两种检测法差值的平均值为2.7 pmol/l,95%一致性界限为-11.7至6.3。
- 若使用Beckman Coulter Access检测法,共有253名(29.3%)女性会接受不恰当的促卵泡激素δ剂量。
- 根据AMH类别不同,49%至90%的女性会基于Access AMH检测法接受较低剂量的促卵泡激素δ。
- 基于Access AMH检测法,高达10%(范围2.5%至10%)的高卵巢储备女性会被错误分类到更大剂量的促卵泡激素δ。
局限性
- 本研究比较了两种主要自动化检测法的数值,将发现外推至其他自动化AMH检测法需要类似的全面检验。
- 需要建立自动化AMH检测的国际校准标准,以促进AMH作为伴随诊断的有效使用。
- 替代自动化AMH检测法的校准差异可能对促卵泡激素δ剂量算法的性能产生不良影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can anti-Müllerian hormone (AMH) automated immunoassays (Elecsys® and Access) be used interchangeably as a companion diagnostic for individualisation of follitropin delta dosing? SUMMARY ANSWER: The Access assay gives systematically higher AMH values than the Elecsys® assay which results in over 29% of women being misclassified to a different follitropin delta dose. WHAT IS KNOWN ALREADY: Follitropin delta is the first gonadotrophin to be licenced with a companion diagnostic, the Roche Elecsys® AMH Plus assay. Alternative automated AMH assays including the Beckman Coulter Access immunoassay are considered to provide similar results, but clarification of their suitability as an off-licence companion diagnostic for follitropin delta is required. STUDY DESIGN, SIZE, DURATION: We systematically searched the existing literature for studies that had measured AMH using both automated assays in the same cohort of women. Individual paired patient data were acquired from each author and combined with unpublished data. PARTICIPANTS/MATERIALS, SETTING, METHODS: We identified five eligible prospective published studies and one additional unpublished study. A 100% response from the authors was achieved. We collected paired AMH data on samples from 848 women. Passing-Bablok regression and Bland-Altman plots were used to compare the analytical performance of the two assays. The degree of misclassification to different treatment categories was estimated should the Access AMH be used as a companion diagnostic instead of the Elecsys AMH in determining the dosing of follitropin delta. MAIN RESULTS AND THE ROLE OF CHANCE: The Passing-Bablok regression shows a linear relationship (Access = -0.05 + 1.10 × Elecsys). The Access assay systematically gave higher values by an average of 10% compared with the Elecsys assay (slope = 1.10, 95% CI: 1.09 to 1.12). The average of the difference between the two assays was 2.7 pmol/l. The 95% limits of agreement were -11.7 to 6.3. Overall 253 (29.3%) women would have received an inappropriate follitropin delta dose if the Beckman Coulter Access assay was used. Specifically, a substantial proportion of women (ranging from 49% to 90% depending on the AMH category) would receive a lower dose of follitropin delta based on the Access AMH assay. Up to 10% (ranging from 2.5% to 10%) of women with high ovarian reserve would have been misclassified to a greater dose of follitropin delta based on the Access AMH assay. LIMITATIONS REASONS FOR CAUTION: We compared the values of the two principal automated assays, extrapolation of our findings to other automated AMH assays would require similar comprehensive examination. WIDER IMPLICATIONS OF THE FINDINGS: An international standard for the calibration of the automated AMH assays is warranted to facilitate efficient use of AMH as a companion diagnostic. The variable calibration of alternative automated AMH assays may adversely impact on the performance of the follitropin delta dosing algorithm. STUDY FUNDING/COMPETING INTEREST(S): No formal funding has been received for this study. SI is funded by a UK Medical Research Council skills development fellowship (MR/N015177/1). SMN has received speakers fees, travel to meetings and participated in advisory Boards for Beckman Coulter, IBSA, Ferring Pharmaecuticals, Finox, Merck Serono, Merck and Roche Diagnostics. SMN has received research support from Ansh laboratories, Beckman Coulter, Ferring Pharmaceuticals and Roche Diagnostics. TRIAL REGISTRATION NUMBER: N/A.
引用
- Iliodromiti S, Salje B, Dewailly D, et al. Non-equivalence of anti-Müllerian hormone automated assays-clinical implications for use as a companion diagnostic for individualised gonadotrophin dosing. Hum Reprod. 2017. PMID: 28854583. doi:10.1093/humrep/dex219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。